RAND:EURONEXT AMSTERDAMRandstad NV Analysis
Data as of 2026-03-14 - not real-time
$11.36
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Rand Capital trades around $11.36, comfortably above its short‑term support of $10.76 yet well below the 30‑day DCF fair value of $37.44, flagging a substantial undervaluation. Technical signals are mixed: the 20‑day SMA (11.48) sits just above price, the 50‑day SMA (11.36) aligns with the market, and the MACD histogram is marginally positive, suggesting a faint bullish bias, while the RSI at 47 indicates neutral momentum. Fundamentals are strained with a –39.9% revenue decline, negative profit margin (‑124%) and trailing EPS of –4.25, though the company holds $4.21 M in cash, carries no debt, and pays a 10.2% dividend yielding a 51% payout ratio. Volume is trending upward, volatility is high at 41% over 30 days, and beta is low (0.25), implying market‑wide moves have limited impact but the stock is nonetheless price‑sensitive.
Given the disparity between market price and intrinsic valuation, the high dividend yield, and the low beta, the stock presents a speculative upside play, but the negative earnings, free‑cash‑flow shortfall, and historic drawdown of over 50% temper enthusiasm. Investors should weigh the attractive yield against sustainability concerns and the company’s uncertain path to profitability before committing.
Given the disparity between market price and intrinsic valuation, the high dividend yield, and the low beta, the stock presents a speculative upside play, but the negative earnings, free‑cash‑flow shortfall, and historic drawdown of over 50% temper enthusiasm. Investors should weigh the attractive yield against sustainability concerns and the company’s uncertain path to profitability before committing.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near immediate support
- Bullish MACD crossover
- Elevated dividend yield
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value far exceeds market price
- Increasing trading volume
- Low beta reducing market‑wide volatility exposure
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Significant valuation gap
- Negative earnings and free‑cash‑flow pressure
- High historical drawdown and liquidity constraints
Key Metrics & Analysis
Financial Health
Revenue Growth-39.90%
Profit Margin-124.17%
ROE-13.68%
ROA5.37%
P/B Ratio0.6
Op. Cash Flow$11.3M
Free Cash Flow$-1786764
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI47.3
Support$10.76
Resistance$12.27
MA 20$11.48
MA 50$11.36
MA 200$14.26
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value$37.44
GradeUndervalued
TypeValue
Dividend Yield10.21%
Risk Assessment
Beta0.25
Volatility41.18%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.